Strategic collaboration expands taletrectinib global reach with a leading oncology partnerEisai will receive exclusive development, registration and commercialization rights for taletrectinib for the ...
Nuvation Bio Inc. , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced preliminary fourth quarter and full year 2025 net product revenue ...
Shilpa Medicare targets US approval of 5-HT3 receptor antiemetic for chemotherapy-induced nausea and vomiting (CINV)Phase 3 study met all primary and secondary endpoints, demonstrating superior ...
PLYMOUTH MEETING, Pa.-- (BUSINESS WIRE)--January 12, 2026-- ...
DENVER, CO / ACCESS Newswire / January 12, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central n ...
The diagnosis and management of invasive fungal infections in adult patients with hematological malignancies remains a ...
Transportation is a key accessibility issue for patients with HR-positive metastatic breast cancer receiving CDK4/6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback